

# Ji-Jin Yao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7923870/publications.pdf>

Version: 2024-02-01

38  
papers

569  
citations

623734

14  
h-index

677142

22  
g-index

40  
all docs

40  
docs citations

40  
times ranked

896  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959). <i>BMC Medicine</i> , 2019, 17, 190.	5.5	64
2	Pretreatment MRI radiomics analysis allows for reliable prediction of local recurrence in non-metastatic T4 nasopharyngeal carcinoma. <i>EBioMedicine</i> , 2019, 42, 270-280.	6.1	49
3	Interobserver variations in the delineation of target volumes and organs at risk and their impact on dose distribution in intensity-modulated radiation therapy for nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2018, 82, 1-7.	1.5	31
4	The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: an observational, prospective analysis. <i>BMC Cancer</i> , 2018, 18, 740.	2.6	31
5	Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis. <i>Chinese Journal of Cancer</i> , 2017, 36, 26.	4.9	30
6	Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma?. <i>Journal of Cancer</i> , 2017, 8, 976-982.	2.5	29
7	Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma. <i>Chinese Journal of Cancer</i> , 2017, 36, 98.	4.9	29
8	Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. <i>Radiotherapy and Oncology</i> , 2019, 137, 137-144.	0.6	26
9	Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area. <i>BMC Cancer</i> , 2019, 19, 37.	2.6	26
10	Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. <i>Radiotherapy and Oncology</i> , 2019, 132, 178-187.	0.6	24
11	Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus <scp>DNA</scp>. <i>Cancer Science</i> , 2017, 108, 1640-1647.	3.9	23
12	A deep-learning-based prognostic nomogram integrating microscopic digital pathology and macroscopic magnetic resonance images in nasopharyngeal carcinoma: a multi-cohort study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097141.	3.2	22
13	Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Cancer Biology and Therapy</i> , 2018, 19, 1102-1107.	3.4	18
14	Critical Evaluation of the Quality and Recommendations of Clinical Practice Guidelines for Nasopharyngeal Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 336-344.	4.9	15
15	The efficacy and toxicity of individualized intensity-modulated radiotherapy based on the tumor extension patterns of nasopharyngeal carcinoma. <i>Oncotarget</i> , 2016, 7, 20680-20690.	1.8	15
16	Dose-volume factors associated with ear disorders following intensity modulated radiotherapy in nasopharyngeal carcinoma. <i>Scientific Reports</i> , 2015, 5, 13525.	3.3	14
17	Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area. <i>Cancer Research and Treatment</i> , 2021, 53, 657-670.	3.0	12
18	A prospective study on radiation doses to organs at risk (OARs) during intensity-modulated radiotherapy for nasopharyngeal carcinoma patients. <i>Oncotarget</i> , 2016, 7, 21742-21752.	1.8	11

#	ARTICLE	IF	CITATIONS
19	Do all patients with advanced N-stage nasopharyngeal carcinoma benefit from the addition of induction chemotherapy to concurrent chemoradiotherapy?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983386.	3.2	10
20	Efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm Phase II study. <i>Cancer Management and Research</i> , 2018, Volume 10, 6985-6996.	1.9	8
21	Prognostic value of serum bilirubin in southern Chinese patients with advanced nasopharyngeal carcinoma. <i>Clinica Chimica Acta</i> , 2018, 484, 314-319.	1.1	8
22	Treatment of Locally Advanced Nasopharyngeal Carcinoma by Helical Tomotherapy: An Observational, Prospective Analysis. <i>Translational Oncology</i> , 2019, 12, 757-763.	3.7	8
23	Neoadjuvant and Concurrent Chemotherapy Have Varied Impacts on the Prognosis of Patients with the Ascending and Descending Types of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy. <i>PLoS ONE</i> , 2016, 11, e0161878.	2.5	8
24	Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study. <i>Radiotherapy and Oncology</i> , 2021, 161, 83-91.	0.6	7
25	Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study. <i>Cancer Cell International</i> , 2021, 21, 604.	4.1	7
26	The Effect of Adding Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Undetectable Pretreatment Epstein-Barr Virus DNA. <i>Translational Oncology</i> , 2017, 10, 527-534.	3.7	6
27	Prognostic Value of Circulating Lipoprotein in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 285-292.	1.6	6
28	The Impact of Clinical Stage on Radiation Doses to Organs at Risk Following Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma: A Prospective Analysis. <i>Journal of Cancer</i> , 2016, 7, 2157-2164.	2.5	5
29	Incidence of and Risk Factors for Mastoiditis after Intensity Modulated Radiotherapy in Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0131284.	2.5	4
30	Predictors of Mastoiditis after Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma: A Dose-Volume Analysis. <i>Journal of Cancer</i> , 2016, 7, 276-282.	2.5	4
31	Prognostic value of primary gross tumor volume and standardized uptake value of 18F-FDG in PET/CT for distant metastasis in locoregionally advanced nasopharyngeal carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831771784.	1.8	4
32	The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort. <i>Translational Oncology</i> , 2021, 14, 100990.	3.7	4
33	The prognostic value of adding systemic inflammation response index to Epstein-Barr virus DNA in childhood nasopharyngeal carcinoma: A real-world study. <i>Head and Neck</i> , 2022, 44, 1404-1413.	2.0	3
34	Dose Escalation of Lobaplatin Concurrent with IMRT for the Treatment of Stage III-IVb NPC: A Phase I Clinical Trial. <i>Translational Oncology</i> , 2018, 11, 1007-1011.	3.7	2
35	Does three cycles of neoadjuvant chemotherapy prior to concurrent chemoradiotherapy provide benefits for all childhood patients with locoregionally advanced nasopharyngeal carcinoma?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2569-2579.	2.5	2
36	The prognostic value of weight loss during radiotherapy among patients with nasopharyngeal carcinoma: a large-scale cohort study. <i>BMC Cancer</i> , 2022, 22, 505.	2.6	2

#	ARTICLE	IF	CITATIONS
37	The Role of Pretreatment 18F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 4157-4166.	4.3	1
38	Development of a web-based prognostic model to quantify the survival benefit of cumulative cisplatin dose during concurrent chemoradiotherapy in childhood nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2022, 166, 118-125.	0.6	1